Delayed Hepatocellular Carcinoma Recurrence After Liver Transplantation: Comprehensive Clinical Characterization of Case Series

References

• Ho CM, Lee PH, Chen CL, Ho MC, Wu YM, Hu RH. Long-term outcomes after resection versus transplantation for hepatocellular carcinoma within UCSF criteria. Ann Surg Oncol. 2012;19(3):826–833. doi:10.1245/s10434-011-1975-x
   PubMed Web of Science ®Google Scholar
• Lee DD, Sapisochin G, Mehta N, et al. Surveillance for HCC after liver transplantation: increased monitoring may yield aggressive treatment options and improved postrecurrence survival. Transplantation. 2020;104(10):2105–2112. doi:10.1097/TP.0000000000003117
   PubMed Web of Science ®Google Scholar
• Ho CM, Lee CH, Lee MC, et al. Survival after treatable hepatocellular carcinoma recurrence in liver recipients: a nationwide cohort analysis. Front Oncol. 2020;10:616094. doi:10.3389/fonc.2020.616094
   PubMed Web of Science ®Google Scholar
• Al-Ameri A, Yu X, Zheng S. Predictors of post-recurrence survival in hepatocellular carcinoma patients following liver transplantation: systematic review and meta-analysis. Transplant Rev. 2022;36(1):100676. doi:10.1016/j.trre.2021.100676
   Web of Science ®Google Scholar
• Sapisochin G, Goldaracena N, Astete S, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series. Ann Surg Oncol. 2015;22(7):2286–2294. doi:10.1245/s10434-014-4273-6
   PubMed Web of Science ®Google Scholar
• Bodzin AS, Lunsford KE, Markovic D, Harlander-Locke MP, Busuttil RW, Agopian VG. Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics. Ann Surg. 2017;266(1):118–125. doi:10.1097/SLA.0000000000001894
   PubMed Web of Science ®Google Scholar
• Schreibman IR, Bejarano P, Martinez EJ, Regev A. Very late recurrence of hepatocellular carcinoma after liver transplantation: case report and literature review. Transplant Proc. 2006;38(9):3140–3143. doi:10.1016/j.transproceed.2006.08.095
   PubMed Web of Science ®Google Scholar
• Hu Z, Zhou J, Li Z, et al. Time interval to recurrence as a predictor of overall survival in salvage liver transplantation for patients with hepatocellular carcinoma associated with hepatitis B virus. Surgery. 2015;157(2):239–248. doi:10.1016/j.surg.2014.09.018
   PubMed Web of Science ®Google Scholar
• Chok KS, Chan SC, Cheung TT, Chan AC, Fan ST, Lo CM. Late recurrence of hepatocellular carcinoma after liver transplantation. World J Surg. 2011;35(9):2058–2062. doi:10.1007/s00268-011-1146-z
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–699. doi:10.1056/NEJM199603143341104
   PubMed Web of Science ®Google Scholar
• Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33(6):1394–1403. doi:10.1053/jhep.2001.24563
   PubMed Web of Science ®Google Scholar
• Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7(3):462–503. doi:10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E
   PubMed Web of Science ®Google Scholar
• Verna EC, Patel YA, Aggarwal A, et al. Liver transplantation for hepatocellular carcinoma: management after the transplant. Am J Transplant. 2020;20(2):333–347. doi:10.1111/ajt.15697
   PubMed Web of Science ®Google Scholar
• Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation. 2003;76(3):597–602. doi:10.1097/01.TP.0000081399.75231.3B
   PubMed Web of Science ®Google Scholar
• Ogawa T, Tashiro H, Miyata Y, et al. Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. Am J Transplant. 2007;7(2):347–355. doi:10.1111/j.1600-6143.2006.01647.x
   PubMed Web of Science ®Google Scholar
• Øzbay LA, Smidt K, Mortensen DM, Carstens J, Jørgensen KA, Rungby J. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. Br J Pharmacol. 2011;162(1):136–146. doi:10.1111/j.1476-5381.2010.01018.x
   PubMed Web of Science ®Google Scholar
• Soleimanpour SA, Crutchlow MF, Ferrari AM, et al. Calcineurin signaling regulates human islet {beta}-cell survival. J Biol Chem. 2010;285(51):40050–40059. doi:10.1074/jbc.M110.154955
   PubMed Web of Science ®Google Scholar
• Chakkera HA, Mandarino LJ. Calcineurin inhibition and new-onset diabetes mellitus after transplantation. Transplantation. 2013;95(5):647–652. doi:10.1097/TP.0b013e31826e592e
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4(3):369–380. doi:10.1016/j.cgh.2005.12.007
   PubMed Web of Science ®Google Scholar
• Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol. 2013;59(6):1193–1199. doi:10.1016/j.jhep.2013.07.012
   PubMed Web of Science ®Google Scholar
• Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727–733. doi:10.1016/j.jhep.2016.06.015
   PubMed Web of Science ®Google Scholar
• Cabibbo G, Petta S, Calvaruso V, et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther. 2017;46(7):688–695. doi:10.1111/apt.14256
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Negro F, Aghemo A, et al. European Association for the Study of the Liver EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170–1218.
   PubMed Web of Science ®Google Scholar
• Probst A, Dang T, Bochud M, Egger M, Negro F, Bochud P-Y. Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis. J Viral Hepat. 2011;18(11):745–759. doi:10.1111/j.1365-2893.2011.01481.x
   PubMed Web of Science ®Google Scholar
• ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016;65(4):734–740. doi:10.1016/j.jhep.2016.05.045
   PubMed Web of Science ®Google Scholar
• Frazzoni L, Sikandar U, Metelli F, et al. Hepatocellular carcinoma recurrence after hepatitis c virus therapy with direct-acting antivirals. a systematic review and meta-analysis. J Clin Med. 2021;10(8):1694. doi:10.3390/jcm10081694
   PubMed Web of Science ®Google Scholar
• Rajendran L, Ivanics T, Claasen MP, Muaddi H, Sapisochin G. The management of post-transplantation recurrence of hepatocellular carcinoma. Clin Mol Hepatol. 2022;28(1):1–16. doi:10.3350/cmh.2021.0217
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of liver diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Alshahrani AA, Ha SM, Hwang S, et al. Clinical features and surveillance of very late hepatocellular carcinoma recurrence after liver transplantation. Ann Transplant. 2018;23:659–665. doi:10.12659/AOT.910598
   PubMed Web of Science ®Google Scholar
• AAM Al-Ameri, Wei X, Wen X, et al. Systematic review: risk prediction models for recurrence of hepatocellular carcinoma after liver transplantation. Transpl Int. 2020;33(7):697–712. doi:10.1111/tri.13585
   PubMed Web of Science ®Google Scholar
• Mehta N, Heimbach J, Harnois DM, et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol. 2017;3(4):493–500. doi:10.1001/jamaoncol.2016.5116
   PubMed Web of Science ®Google Scholar
• Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143(4):986–94.e3; quiz e14–5. doi:10.1053/j.gastro.2012.05.052
   Web of Science ®Google Scholar
• Decaens T, Roudot-Thoraval F, Badran H, et al. Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma. Liver Int. 2011;31(6):792–801. doi:10.1111/j.1478-3231.2010.02425.x
   PubMed Web of Science ®Google Scholar
• Trevisani F, Garuti F, Cucchetti A, Lenzi B, Bernardi M. De novo hepatocellular carcinoma of liver allograft: a neglected issue. Cancer Lett. 2015;357(1):47–54. doi:10.1016/j.canlet.2014.11.032
   PubMed Web of Science ®Google Scholar
• Adam R, McMaster P, O’Grady JG, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl. 2003;9(12):1231–1243. doi:10.1016/j.lts.2003.09.018
   PubMed Web of Science ®Google Scholar
• Angelico M, Cillo U, Fagiuoli S, et al. Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis. 2011;43(2):155–164. doi:10.1016/j.dld.2010.11.002
   PubMedGoogle Scholar
• Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332(22):1463–1466. doi:10.1056/NEJM199506013322202
   PubMed Web of Science ®Google Scholar
• Sauer S, Reed DR, Ihnat M, Hurst RE, Warshawsky D, Barkan D. Innovative approaches in the battle against cancer recurrence: novel strategies to combat dormant disseminated tumor cells. Front Oncol. 2021;11:659963. doi:10.3389/fonc.2021.659963
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. doi:10.1126/scitranslmed.3007094
   PubMed Web of Science ®Google Scholar
• Huang T, Deng CX. Current progresses of exosomes as cancer diagnostic and prognostic biomarkers. Int J Biol Sci. 2019;15(1):1–11. doi:10.7150/ijbs.27796
   PubMed Web of Science ®Google Scholar
• Mathew M, Zade M, Mezghani N, Patel R, Wang Y, Momen-Heravi F. Extracellular vesicles as biomarkers in cancer immunotherapy. Cancers. 2020;12(10):2825. doi:10.3390/cancers12102825
   PubMed Web of Science ®Google Scholar
• von Felden J, Villanueva A. Role of molecular biomarkers in liver transplantation for hepatocellular carcinoma. Liver Transpl. 2020;26(6):823–831. doi:10.1002/lt.25731
   PubMed Web of Science ®Google Scholar